Intabio to Present Latest Advance in Biopharmaceutical Quality Characterization at WCBP Conference
NEWARK, Calif., Jan. 22, 2019 /PRNewswire/ -- Intabio, Inc. today announced it will showcase the latest advances in high-resolution imaged capillary isoelectric focusing (cIEF) coupled to electrospray ionization mass spectrometry (ESI-MS) at January's WCBP Conference in Washington, D.C. Erik Gentalen, CTO, will highlight intact antibody characterization data from Intabio's Blaze™ system interfaced to MS on Wednesday, January 30 during the WCBP Technical Seminar sponsored by Bruker Corporation. Recent results from work with Intabio's Early Access Pharma partners will be presented.
Bruker was Intabio's first partner to collaboratively develop an MS interface for the Blaze system, and data demonstrating the successful integration of the two systems will be discussed. Intabio currently is designing interfaces for other leading high-resolution MS systems.
Dr. Rohan Thakur, Executive Vice President, Bruker Daltonics said, "The potential for robust biopharmaceutical characterization through the coupling of the Blaze microchip based cIEF system to Bruker's UHR-QTOF mass spectrometers could be a game changing proposition. The unique design of Bruker's ion source allows for optimal cIEF-MS coupling which offers several advantages for automation, and while the MS systems have a market leading reputation for the analysis of intact proteins, enabling user with such differentiating technology will likely have an impact on safety as well as speed to clinic for biopharmaceuticals."
Intabio's Blaze platform performs a comprehensive analysis of antibody and protein biopharmaceutical product quality with blazing speed, offering 100-fold higher throughput over traditional methods. Blaze assays use microchip functionality to integrate (1) separation of protein isoforms by isoelectric focusing, (2) 280-nm imaging of protein isoforms for quantitation, and (3) ESI for delivery of the separated isoforms to an adjacent MS for peak identification. Each sample analysis requires only minutes.
"The Blaze system's ability to run imaged cIEF separations and then continue to maintain exceptional peak resolution during mobilization into the MS is a breakthrough advancement for protein quality determination," said Gentalen. "We believe Intabio's microchip approach enables routine mass analysis of individual protein charge variants for the first time."
Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. For more information, please visit us at www.intabio.com.